These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Jordanian pharmaceutical companies: are their marketing efforts paying off? Al-Shaikh MS; Torres IM; Zuniga MA; Ghunaim A Health Mark Q; 2011 Apr; 28(2):174-89. PubMed ID: 21590563 [TBL] [Abstract][Full Text] [Related]
23. The regulatory framework for similar biotherapeutic products in Cuba. Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393 [TBL] [Abstract][Full Text] [Related]
24. The acceptable face of international competition. Stereophobia: an economic afterthought. Ariëns EJ Trends Pharmacol Sci; 1988 Sep; 9(9):317. PubMed ID: 3270968 [No Abstract] [Full Text] [Related]
25. America's pharmaceutical research companies: keeping the cost of health care down. Pharmaceutical Manufacturers Association. Hawaii Med J; 1992 Jan; 51(1):15-16, 19. PubMed ID: 1740387 [No Abstract] [Full Text] [Related]
26. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
27. Out in the open. Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130 [No Abstract] [Full Text] [Related]
28. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
29. Impact of gatt agreement on drug prices. Pillai AM J Indian Med Assoc; 1995 Mar; 93(3):113, 120. PubMed ID: 8522810 [No Abstract] [Full Text] [Related]
30. Comment on: developing good scientific publishing practices: one pharmaceutical company's perspective. Norris RA Curr Med Res Opin; 2010 Jul; 26(7):1675-6. PubMed ID: 20450261 [No Abstract] [Full Text] [Related]
31. The danger of in-kind drug donations to the Global Fund. Baker BK; Ombaka E Lancet; 2009 Apr; 373(9670):1218-21. PubMed ID: 18848353 [No Abstract] [Full Text] [Related]
32. Pharmaceutical GMPs. Bobrowicz G Qual Assur; 1994 Jun; 3(2):138-48. PubMed ID: 7804629 [No Abstract] [Full Text] [Related]
33. A comparative analysis of quality management standards for contract research organisations in clinical trials. Murray E; McAdam R Int J Health Care Qual Assur; 2007; 20(1):16-33. PubMed ID: 18240505 [TBL] [Abstract][Full Text] [Related]
34. Corporate compliance programs for FDA-regulated companies: incentives for their development and the impact of the federal sentencing guidelines for organizations. Freyer DH Food Drug Law J; 1996; 51(2):225-42. PubMed ID: 11820200 [No Abstract] [Full Text] [Related]
35. "Good Publication Practice for Pharmaceutical Companies": where are we now? Wager E MedGenMed; 2005 Apr; 7(2):6. PubMed ID: 16369385 [TBL] [Abstract][Full Text] [Related]
37. Application of ISO 9002 and FDA's good manufacturing practices to general chemical manufacturing. Kauffman JM; Weiler ED Qual Assur; 1992 Jun; 1(3):213-6. PubMed ID: 1344676 [TBL] [Abstract][Full Text] [Related]
38. This Dutchman is flying. Watson N Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720 [No Abstract] [Full Text] [Related]
39. Evaluation of similar biotherapeutic products: scientific and regulatory challenges. Griffiths E; Thorpe R; Wadhwa M; Sohn Y Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898 [No Abstract] [Full Text] [Related]
40. Management of quality, capacity, and productivity at Merck. Nathan J; Venkataraman R Hosp Mater Manage Q; 1999 Feb; 20(3):64-9. PubMed ID: 10345635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]